key: cord-0260596-9phhjsah authors: Chu, L.; Montefiori, D.; Huang, W.; Nestorova, B.; Chang, Y.; Carfi, A.; Edwards, D. K.; Oestreicher, J.; Legault, H.; Girard, B.; Pajon, R.; Miller, J. M.; Das, R.; Leav, B.; McPhee, R. title: Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) date: 2021-10-01 journal: nan DOI: 10.1101/2021.09.29.21264089 sha: 92e753e508854a8b4f639c5b68bd5b81c0a73c37 doc_id: 260596 cord_uid: 9phhjsah Rising breakthrough infections of coronavirus-2 (SARS-CoV-2) in previously immunized individuals has raised concerns for a potential booster to combat suspected waning immunity and new variants. In this study, participants immunized 6-8 months earlier with a primary series of two doses of 50 or 100 g of mRNA-1273 were administered a booster injection of 50 g of mRNA-1273. Neutralizing antibody levels at one month after the booster were 1.7-fold higher than those one-month post primary series second injection meeting the prespecified criteria for noninferiority, and indicating an immune memory response. The reactogenicity after the booster dose was similar to that after the second dose in the primary series of two doses of mRNA-1273 (50 or 100 g) with no serious adverse events reported in the one-month follow-up period. These results demonstrate that a booster injection of mRNA-1273 in previously immunized individuals stimulated an immune response greater than the primary vaccination series. Several vaccines for severe acute respiratory coronavirus-2 (SARS-CoV-2) have been authorized for emergency use, and one vaccine has been approved by the U.S. FDA for immunization of individuals ≥16 years of age. On September 22, 2021, the U.S. FDA approved a third dose of BNT162b2 in individuals ≥65 years of age, those 18 to 64 years of age at high risk of severe COVID-19, and those who have institutional or occupational exposure to SARS-CoV-2 which puts them at high risk of serious complications of COVID-19. 1 SARS-CoV-2 vaccines have been administered worldwide to billions of people. [2] [3] [4] These vaccines are very efficacious in preventing hospitalizations and deaths due to COVID-19. 5-7 mRNA-1273 is a lipid nanoparticleencapsulated messenger RNA encoding the S protein of the Wuhan-Hu-1 isolate with 2 proline mutations introduced to stabilize the S protein into the prefusion conformation. mRNA-1273 has demonstrated immune responses against SARS-CoV-2, efficacy against COVID-19 disease in adults and adolescents and an acceptable safety and tolerability profile in several clinical trials. 5, [8] [9] [10] [11] Based on a vaccine efficacy of 94.1% against COVID-19 after a median follow up of 64 days 5 , demonstrated in the phase 3 COVE study, mRNA-1273 received emergency use authorization from the Food and Drug Administration in December, 2020 for use in adults 18 years of age or older. 12 Recently, the final efficacy analysis of the blinded part of the study demonstrated a vaccine efficacy of 93.2% over 5.3 months of follow-up. 13 There are concerns that the efficacy of the SARS-CoV-2 vaccines may decrease in the future due to waning immunity and/or emerging viral variants. Variants of SARS-CoV-2 with amino acid changes in the spike protein (S) and elsewhere in the viral genome are circulating There were two age cohorts in this phase 2 study: participants ≥18 to <55 years old in Cohort 1 and participants ≥ 55 years old in Cohort 2. Within each age cohort, approximately 300 participants were randomized in 1:1:1 ratio to receive 50 µg of mRNA-1273, 100 µg of mRNA-1273, or placebo in Part A. The randomization was performed in a blinded manner using a centralized Interactive Response Technology. Vaccine dose preparation and administration during Part A were performed by unblinded pharmacy personnel who did not participate in any other aspects of the study. A limited number of the sponsor team and clinical research organization (CRO) were unblinded to enable the primary analysis at one month after the second dose of mRNA-1273 in Part A. All study staff, participants, CRO and sponsor personnel remained blinded to dosing assignment until the study was unblinded, upon implementation of Part B of the study, following Emergency Use Authorization of mRNA-1273 in the United States. Participants with negative baseline SARS-CoV-2 status (n=1080) were randomly selected from the phase 3 COVE trial participants in the mRNA-1273 group to form an Immunogenicity Subset which was subsequently used as the historical comparator arm for the phase 2 Part B immunobridging analysis. Of the 1080 selected participants from the phase 3 COVE trial mRNA- The mRNA-1273 vaccine is a lipid nanoparticle containing an mRNA that encodes the SARS-CoV-2 spike glycoprotein of the Wuhan-HU-1 isolate. 9, 11 The placebo and the mRNA-1273 vaccine were administered in the deltoid as an intramuscular injection according to a 2-dose regimen in Part A with the first dose given on day 1 and the second on day 29 (28 days after dose 1). In Part B, 50 µg of mRNA-1273 was administered intramuscularly in the deltoid as a single booster injection at Open-label Day 1 (OL-D1) to the treatment groups originally vaccinated with either dose regimen of mRNA-1273. The volume administered in both Part A and Part B in each injection was 0.5 mL containing 50 or 100 µg of mRNA-1273, or saline (placebo). Details regarding the design of Part A of the study have been previously published. 28 The primary safety objective of Part B was to evaluate the safety and reactogenicity of 50 µg of mRNA-1273 administered as a single booster dose 6 months or more after a priming series of 50 µg or 100 µg of mRNA 1273. The primary safety endpoints were solicited local and systemic adverse reactions (ARs) through 7 days after each injection, unsolicited treatment-emergent adverse events (TEAEs) through 28 days after each injection, medically-attended AEs (MAAEs) and serious AEs (SAEs) throughout the entire study period. The primary immunogenicity objective was to evaluate the immunogenicity of 50 µg of mRNA-1273 administered as a single booster dose administered at least 6 months after a twodose priming series with 50 or 100 µg of mRNA-1273 as compared to 100 µg of mRNA-1273 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint administered as 2 doses 28 days apart in the pivotal phase 3 efficacy and safety study (COVE-P301), as assessed by the level of SARS-CoV-2-specific neutralizing antibody (nAb). The coprimary endpoints for noninferiority were: (i) Geometric mean (GM) titers of serum nAb and (ii) Seroresponse rates for nAb based on the pseudovirus neutralizing antibody assay. The secondary immunogenicity objective was to evaluate the immunogenicity of 50 µg of mRNA-1273 vaccine administered as a single booster dose as assessed by the titers of bAb. Levels of SARS-CoV-2-specific bAb were measured by enzyme-linked immunosorbent assay (ELISA) and a SARS-CoV-2 Meso-Scale Discovery (MSD) 3-PLEX assay on OL-D1 (pre-boost) and OL-D29 (28 days after the booster injection). Seroresponse was defined in 3 ways: i) seroresponse (specific to the ID50 titer in the pseudovirus neutralizing antibody assay) was defined as a change from below the lower limit of quantification (LLOQ) at pre-booster (or pre-dose 1) to equal or above LLOQ at 28 days after the booster (or 28 days after the primary series), or at least a 3.3-fold rise at 28 days after the booster (or 28 days after the primary series) if pre-booster (or pre-dose 1) titer was equal to or above LLOQ; ii) Seroresponse (4-fold rise) was defined as a change of titer from below the LLOQ at pre-booster (or pre-dose 1) to equal to or above 4 × LLOQ at 28 days after the booster (or 28 days after the primary series), or a 4-times or higher ratio in participants with titers above the LLOQ at pre-booster (or pre-dose 1); and iii) Seroresponse (4fold rise from baseline) was defined as a change of titer from below the LLOQ at pre-dose 1 to equal to or above 4 × LLOQ at 28 days after the booster (or 28 days after the primary series), or a 4-times or higher ratio in participants with titers above the LLOQ at pre-dose 1. Definition iii) was applied on participants in the Phase 2 study only, primary series in Part A and booster in Part B. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Solicited local and systemic adverse reactions were recorded daily by participants in an electronic diary during the 7 days after vaccine administration. Any solicited adverse reaction that persisted beyond Day 7 was reported in the electronic diary until resolution. Oral body temperatures were measured daily. If applicable, the size of injection site erythema and swelling/induration were measured and recorded. In Part B, trained site personnel called trial participants every 4 weeks to assess safety beginning 3 months after the booster dose. This validated assay quantifies SARS-CoV-2 neutralizing antibodies by using lentivirus particles that express SARS-CoV-2 spike proteins (Wuhan-Hu-1 isolate including D614G or the 29 The virus was applied to transduced 293T cells expressing high levels of ACE2 (293T/ACE2 cells), with or without pre-incubation with antibodies (control antibodies or serum samples); the presence of neutralizing antibodies reduced infection and resulted in lower RLUs. Serial dilution of antibodies or serum samples were used to produce a dose-response curve. Neutralization was measured as the serum dilution at which the RLU was reduced by 50% (50 percent inhibitory dose [ID50]) or 80% (80 percent inhibitory dose [ID80]) relative to mean RLU in virus control wells (cells + virus but no control antibody or sample) after subtraction of the mean RLU in cell control wells (cells only). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This quantitative electrochemiluminescence (ECL) method is an indirect binding ECL method designed to detect SARS-CoV-2 antibodies [SARS-CoV-2 Spike (S; Wuhan-Hu-1 isolate including D614G), nucleocapsid (N), and receptor binding domain (RBD) antibodies] in human serum. The assay is based on the Meso-Scale Discovery (MSD) technology which employs capture molecule MULTI-SPOT® microtiter plates fitted with a series of electrodes. Using an MSD MESO Sector S 600 detection system, an electrical current was applied to the custom microtiter plates leading to a light emission by SULFO-TAGTM through a series of oxidationreduction reactions involving ruthenium and tripropylamine (TPA). A plate reader measured the intensity of emitted light to provide quantitative measures of analytes in samples. For this bioassay, a 10-spot custom SARS-CoV-2 3-PLEX plate coated with SARS-CoV-2 antigens (S [containing D614G], N, and RBD) was used. Anti-SARS-CoV-2 antibodies present in the test sample bound to the antigen coated plates and formed an antibody-antigen complexes. These complexes were detected by adding SULFO-TAGTM-labeled antibodies, which bind to the antibody-antigen complexes. Addition of TPA in a buffer solution resulted in ECL that was measured in relative light units (RLU) using the MSD SECTOR S 600 Plate Reader. Antibody concentrations were determined by interpolating their ECL response using the standard curve generated from a serially diluted reference standard. This validated assay uses microtiter plates coated with commercially available SARS-CoV-2 full-length spike glycoprotein [Wuhan-Hu-1 isolate including D614G]. Serum containing the SARS-CoV-2 IgG antibody was added to the plates. Bound antigen-antibody complex was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint detected using purified goat anti-human IgG horseradish peroxidase conjugate. Color development occurred with the addition of 3,3′,5,5′tetramethylbenzidine substrate and color intensity was measured spectrophotometrically (450 nm). The intensity of the color was directly proportional to the IgG antibody concentration. Quantitation of the human IgG antibody to SARS-CoV-2, or antibody concentration (AU/mL), was determined by interpolation from a standard curve analyzed on each assay plate. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint The results for the two groups that received a booster injection after a primary series of two doses of 50 µg or 100 µg of mRNA-1273 were expected to be similar and have been combined for the immunogenicity analysis to increase the statistical power for comparisons to the historical control from the phase 3 COVE trial. The safety analyses were descriptive without pre-specified statistical criteria. The Safety The geometric mean titers (GMT) of bAb or nAb titers with corresponding 95% CI were provided at each time point. The GM fold-rise (GMFR) of bAb or nAb titers and the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint corresponding 95% CI were also provided. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMT and GMFR, respectively, then back transformed to the original scale for presentation. For calculation of GMTs and GMFRs, antibody values reported as below the LLOQ were replaced by 0.5 × LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. Missing results were not be imputed. To assess the magnitudes of the differences in immune response 28 days after a single booster dose of 50 μg mRNA-1273 and the immune response 28 days after the completion of the primary series of mRNA-1273 100 μg in the phase 3 COVE study, an analysis of covariance (ANCOVA) model was used. The model included log-transformed antibody titers at D29 after booster in this phase 2 study, and D57 in COVE study as the dependent variable, treatment groups (50 μg mRNA-1273 booster in phase 2, 100 μg primary series in COVE) as explanatory variable, adjusting for age groups (< 65, ≥ 65; age group used in COVE Study). The geometric least squares mean (GLSM) and corresponding 2-sided 95% CI for the antibody titers for each treatment group were provided. The GLSM, and the corresponding 95% CI results in logtransformed scale estimated from the model were back-transformed to obtain these estimates in the original scale. GMR, estimated by the ratio of GLSM and the corresponding 2-sided 95% CI were provided to assess the treatment difference. The primary immunogenicity objective in Part B was considered met if the noninferiority based on both GM titers and seroresponse rate at 28 days after the booster in Part B compared with 28 days after the second dose in the phase 3 COVE trial was demonstrated, at a 2-sided alpha of 0.05. The null hypotheses based on GM titers and seroresponse rate and the criterion All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint of success included: Noninferiority based on the GMR (28 days after the booster in Part B versus 28 days after the second dose in the phase 3 COVE trial) was predefined with a noninferiority margin of 1.5 and a point estimate of GMR ≥ 1; and noninferiority based on difference in seroresponse rate (28 days after the booster in Part B minus 28 days after the second dose in the phase 3 COVE trial) was predefined with a noninferiority margin of 10%. All analyses were conducted using SAS Version 9.4 or higher. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The Phase 2 Part A trial consisted of a total of 600 participants. Of the 344 participants who received a booster dose in Part B, 173 received two doses of 50 µg of mRNA-1273 and 171 received two doses of 100 µg of mRNA-1273 6 to 8 months earlier in Part A ( Figure 1 ). The baseline demographic characteristics of the participants who received a booster injection were generally similar between the groups that received a primary series of 50 µg or 100 µg of mRNA-1273 and the group in the phase 3 COVE that received 2 doses of mRNA-1273 (Table 1 ). The majority of participants were White and not Hispanic or Latinx in the P201 and COVE trials, but there were higher percentages of Black and Hispanic or Latinx participants in the latter. The mean age of the participants in the groups that received the booster was 52.0 years in P201 Part B and 54.5 years for those who received 2 doses in the phase 3 COVE trial. The time intervals (mean [standard deviation; range]) between the second dose of mRNA-1273 during the primary series and the booster injection was 7.2 [0.6; 6.1-9.0] months for the group that received 50 µg of mRNA-1273 and 7.2 [0.6; 5.9-8.6] months for the group that received 100 µg of mRNA-1273 during the primary series. The percentages of participants with any solicited local or systemic adverse reactions within seven days of the last injection were generally similar between the group that received a booster injection after a primary series of 50 µg or 100 µg of mRNA-1273 (Part B), the group in the phase 3 COVE trial that received two doses of 100 µg of mRNA-1273, and the group in this trial during the blinded phase (Part A) after they received two doses of mRNA-1273 (Figures 2A All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 ). There were no Grade 4 solicited local or systemic adverse events after the booster injection. The most common local adverse reaction was injection-site pain in 86.3% of those in the pooled group that received the 50 µg and 100 µg prime and 88.3% of those in the phase 3 COVE trial (Supplementary Table 1 ). The most common Grade 3 local adverse reaction was injectionsite pain in 4.0% of the participants in the pooled 50 and 100 µg prime group and 4.1% of those in the phase 3 COVE trial (Supplementary Table 1 Table 1 Table 2 ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 ). The percentages of participants with any solicited local or systemic adverse reactions were generally similar between the groups that received a booster injection and were ≥18 to <55 years of age compared to those who were ≥55 years of age (Supplementary Table 3 ). Thirteen participants (3.8%) reported treatment-emergent adverse events related to study vaccination up to 28 days after the booster injection, but none led to study discontinuation (Supplementary Table 7 ). There were no serious adverse events up to 28 days after the booster injection. The GMTs [95% confidence interval] in the D614G pseudovirus neutralizing antibody assay at Day 57 (28 days after the second injection of mRNA-1273 during the primary series) Table 4 ). At OL-Day 29 (28 days All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. Table 4 ). The difference in the GM fold rises between the 50 and 100 µg groups is most likely due to differences in the GMTs in these 2 groups at one month after the second injection of mRNA-1273 ( Figure 3 ; Supplementary Table 4 ). The neutralizing antibody levels at 28 days after the booster dose of mRNA-1273 in participants in Part B of this study were also higher than those at 28 days after the second dose of mRNA-1273 in participants in the pivotal phase 3 COVE trial (Table 2 ). In a comparison of the pseudovirus neutralizing antibody titers against D614G at 28 days after the booster dose with those in the phase 3 COVE trial at 28 days after the second dose (in which vaccine efficacy was demonstrated 5 ), the geometric mean ratio (GMR) was 1.7 (95% CI: 1.5, 1.9) ( Table 2 ). This GMR of 1.7 was above the prespecified threshold of 1.0 and the lower bound of the 95% CI was greater than 0.67 (corresponding to a noninferiority margin of 1.5). Therefore, the prespecified criteria for noninferiority were met for both the GMT ratio and the seroresponse difference. In a comparison of the pseudovirus neutralizing antibody titers against the Delta variant at 28 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 ). The seroresponse rates in the pseudovirus neutralizing antibody assay were noninferior in the phase 2 Part B group after the booster injection compared to the phase 3 COVE trial after the primary series (Table 3) , based on the assay-specific seroresponse definition. Given that the lower limit of the 95% confidence interval for the group difference in seroresponse rates (4-fold rise from baseline) was greater than 0, the observed seroresponse rates are statistically significantly higher after the booster dose than after the second dose in Part A of the phase 2 study. In the pooled Part B group (previously primed with 2 doses of either 50 or 100 ug mRNA-1273, n=293), the pre-booster nAb GMT versus the Delta variant was 42.3 (95% CI, 37.2, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. which is similar to the 2.9-fold difference (GMTs=354 against Delta, and 1032.7 against D614G; Table 2 ) seen 28 days after the primary series of two doses of 100 µg mRNA-1273 in the phase 3 COVE study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this study, the administration of a booster dose of 50 µg mRNA-1273 to participants approximately 6 to 8 months after a primary series of two doses of 50 or 100 µg of mRNA-1273 resulted in a safety profile that was comparable to that in the group in the phase 3 COVE trial after receiving the second dose of mRNA-1273 in the primary series. After receiving the booster injection of mRNA-1273, the most common local adverse reaction was pain, and the most common systemic adverse reactions were fatigue, headache and myalgia. The incidence and severity of local and systemic adverse reactions was similar to that observed in Part A of this study and the phase 3 COVE trial after the second injection of mRNA-1273. 5, 11 Both co-primary immunogenicity objectives were met for the pooled group that received a booster (Part B) compared to the group in the phase 3 COVE trial that received two doses of mRNA-1273. Neutralizing antibody titers (pseudovirus neutralizing antibody) against the D614G strain of virus at 28 days after the booster injection were higher than the levels at 28 days after the second dose of mRNA-1273 during the primary series in the pivotal phase 3 efficacy trial (COVE study). This higher level of antibody after the booster injection compared to the second injection is indicative of a robust immune memory response likely due to stimulation of memory B cells. [30] [31] [32] [33] It is also important to note that the results here using a validated pseudovirus neutralization assay showed that the GMTs after the second dose of mRNA-1273 were higher at one month after the second dose in the 100 µg group (1268.0; 95% CI=1087.9, 1477.8) compared to the 50 µg group (629.2; 549.3, 720.8) (Figure 3; Supplementary Table 4 ). Previous results using a qualified live virus neutralizing antibody assay showed similar GMTs at one month after the second dose of 100 µg compared to 50 µg (~1640). 28 These different All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. There are several limitations to the results of this study. This study was designed to assess the safety and immune response of a third dose of mRNA-1273 administered at least 6 months after the initial priming series. While the optimal timing of a third dose has not been established, the data from this trial provides important information to address the need for third booster dose in case of waning vaccine effectiveness. Although neutralizing antibody responses have been correlated to reduction of risk for breakthrough COVID-19 disease, 37 a threshold of protection has not been defined for the Wuhan-1 or Delta variants. Also, this study did not examine variant-specific booster vaccines or immune responses to variants of concern other than for Delta. Finally, this study showed an immune memory antibody response to the spike protein of SARS-CoV-2 but did not examine T cell memory or quantify B memory cells. While the data supporting the timing of when booster doses of mRNA vaccine against SARS-CoV-2 should be administered is still evolving, the results from this study provide evidence that a third dose of mRNA-1273 administered at least 6 months after the primary series is safe and effective in inducing a booster response, as indicated by the statistically significantly higher antibody titers observed after the 50 µg booster dose as compared to after the second priming dose of 100 µg of mRNA-1273. A booster dose of mRNA-1273 has the potential for establishing durable vaccine efficacy and restoring neutralizing antibody capability. The increased antibody responses to the Delta variant suggest that a third dose of mRNA-1273 may provide improved protection against this variant of concern. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. Employees of the study sponsor, Moderna, Inc., contributed to the study design, data collection, analysis and interpretation, and writing of this manuscript. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Legend: The percentage of participants in the Solicited Safety Set who reported local (A) or systemic (B) solicited adverse reactions is shown for 330 participants who received a booster dose of mRNA-1273 (50 μg) after a primary series of two doses of 50 or 100 µg of mRNA-1273 in Part B, 198 participants who received a booster dose of mRNA-1273 (50 μg) after a primary series of two doses of 100 µg of mRNA-1273 in Part B, and 14691 participants who received two doses of 100 µg of mRNA-1273 in the phase 3 COVE trial. The percentages of participants who submitted any data for the adverse event within seven days after the booster injection or the second dose during the primary series are shown. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint The geometric mean titers (GMTs) and 95% confidence intervals (95% CIs) against the D614G virus for serum samples collected in Part A at baseline, 28 days after the first dose of mRNA-1273, 28 days after the second dose of mRNA-1273, and in Part B before the booster injection of 50 µg of mRNA-1273 (Pre-booster) and 28 days after the booster injection. Antibody values in the pseudovirus assay reported as below the lower limit of quantification (LLOQ; 18.5) were replaced by 0.5 x LLOQ. Values that were greater than the upper limit of quantification (ULOQ; 45118) were changed to the ULOQ if actual values were not available. 95% Confidence Intervals were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMT, then back transformed to the original scale. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09. 29.21264089 doi: medRxiv preprint Age was defined at the screening in Part A. Percentages are based on the number of participants in the safety set. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI = confidence interval; ID50 = 50% inhibitory dilution; LLOQ = lower limit of quantification. N1 = Number of participants with nonmissing data at both post-baseline timepoint of interest and baseline. For participants who received the primary series in phase 3 COVE, seroresponse was defined based on the fold-rise at Day 57 (28 days after the second dose of mRNA-1273) compared to the baseline titer (prior to first dose of primary dose). * Seroresponse specific to the ID50 titer in the D614G pseudovirus neutralizing antibody assay at a participant level was defined as a change from below LLOQ to equal or above LLOQ, or at least a 3.3fold rise if baseline was equal to or above LLOQ. § For participants who received a booster vaccination in Phase 2, Part B, seroresponse was defined based on the fold-rise at OL-D29 (28 days after the booster dose of mRNA-1273) compared to the pre-booster titer (OL-D1; at least 6 months after completion of the primary series). † Seroresponse at participant level was defined as a change of titer in the D614G pseudovirus neutralizing antibody assay from below the lower limit of quantification (LLOQ) to equal to or above 4 × LLOQ, or a 4-times or higher ratio in participants with titers above LLOQ. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint ‡ Seroresponse at participant level was defined as a change of titer in the D614G pseudovirus neutralizing antibody assay from below the lower limit of quantification (LLOQ) to equal to or above 4 × LLOQ, or a 4-times or higher ratio in participants with titers above LLOQ. || For participants who received a booster vaccination in Phase 2, Part B, seroresponse was defined based on the fold-rise at OL-D29 (28 days after the booster dose of mRNA-1273) compared to the baseline titer (prior to first dose of primary dose). ¶ 95% CI was calculated using the Clopper-Pearson method. # For the 4-Fold Rise from Baseline Definition, the difference in seroresponse rate was the fold rise in Phase 2 Part B at OL-D29 (28 days after the booster dose of mRNA-1273) compared to 28 days after the second dose during the primary series in Phase 2 Part A. ** 95% CI was calculated using the Miettinen-Nurminen (score) confidence limits. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264089 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Percentages are based on the number of exposed subjects who submitted any data for the event (N1). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .3) N1 = Number of exposed subjects who submitted any data for the event. NR = not reported. Percentages are based on the number of exposed subjects who submitted any data for the event (N1). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 1 (1.4) 0 1 (0.7) 1 (1.1) 0 1 (0.6) N1=Number of exposed participants who submitted any data for the event. Percentages are based on the number of exposed participants who submitted any data for the event (N1). 3 Antibody values reported as below the lower limit of quantification (LLOQ; 18.5) were replaced by 0.5 x LLOQ. Values that were greater than the upper limit of quantification (ULOQ; 45118) were converted to the ULOQ if actual values were not available. *n=Number of subjects with non-missing baseline results. † 95% Confidence Intervals were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMT and GMFR, respectively, then back transformed to the original scale. ‡ Number of subjects in the Per-Protocol Set with non-missing data at the corresponding visit. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 x LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values are not available. Percentages are based on the number of participants in the Per-Protocol Set with non-missing data at baseline and the corresponding visit. 95% Confidence Intervals were calculated based on the t-distribution of the log-transformed values or the difference in the logtransformed values for GMT and GMFR, respectively, then back transformed to the original scale for presentation. Table 7 : A treatment-emergent adverse event was defined as any event not present before exposure to study vaccination or any event already present that worsens in intensity or frequency after exposure. Percentages are based on the number of participants in the safety set. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 8 : Antibody values reported as below the lower limit of quantification (LLOQ; 18.5) were replaced by 0.5 x LLOQ. Values that were greater than the upper limit of quantification (ULOQ; 45118) were converted to the ULOQ if actual values were not available. *n=Number of participants with non-missing results at pre-booster. † 95% Confidence Intervals were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMT and GMFR, respectively, then back transformed to the original scale. ‡ Number of participants in the Per-Protocol Set with non-missing data at the corresponding visit. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines (Basel) Coronavirus Pandemic (COVID-19) Approves First COVID-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine FDA. Moderna COVID-19 Vaccine Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase CDC. SARS-CoV-2 Variant Classifications and Definitions Variant Proportions Overview of Variants in Countries Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates Neutralizing Activity of BNT162b2-Elicited Serum -Preliminary Report Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant & National Study Group for, C.-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine -Preliminary Report Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines B cell memory: building two walls of protection against pathogens Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of From vaccines to memory and back Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults -United States New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status Comparative Effectiveness of Moderna Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial MedRxiv We thanks the participants in this trial and the phase 2 Study Investigators; the Immune Assay seroresponse rates, % (95% CI) † -1.2 (-3.5, 0.0) * Overall: Combined 50 µg and 100 µg prime groups † Seroresponse at participant level was defined as a change of titer from below the lower limit of quantification (LLOQ) to equal to or above 4 times the LLOQ, or a 4-times or higher ratio in participants with titers above LLOQ. The difference in seroresponse rates was Boosting minus Primary Series. For participants who received the primary series, seroresponse was defined based on the fold-rise from baseline titer (prior to first dose of primary dose). For participants who received a booster vaccination, seroresponse was defined based on the fold-rise from pre-booster titer (at least 6 months after completion of the primary series). GMT: Observed